The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of acalabrutinib for the treatment of R/R MZL
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the safety and efficacy of acalabrutinib for the treatment of relapsed/refractory marginal zone lymphoma (R/R MZL). Dr Strati first comments on the efficacy of acalabrutinib compared to ibrutinib, and then goes on to discuss the results of a study evaluating the use of acalabrutinib in R/R MZL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisory Board/Consultancy: Roche Genentech, Hutchinson MediPharma, ADC Therapeutic, TG Therapeutics, Incyte Morphosis, Kite Gilead
Research Support: Astrazeneca Acerta, ADC Therapeutics, Sobi Pharmaceutics, ALX Oncology
